Advertisement

Obesity pp 199-210 | Cite as

Polycystic Ovary Syndrome and Obesity

  • Thomas M. BarberEmail author
  • George K. Dimitriadis
  • Stephen Franks

Abstract

Polycystic Ovary Syndrome (PCOS) is a common condition in reproductive-age women. PCOS is characterized by both reproductive dysfunction and hyperandrogenemia. Importantly, PCOS is also associated with metabolic aberrations, including insulin resistance. There is a strong association between obesity and PCOS, based on epidemiology, aetiology and genetics studies. Increased adiposity worsens insulin resistance (which in turn results in compensatory hyperinsulinemia, with associated pleiotropic effects) and disrupts steroid metabolism, further enhancing androgenicity. Through these mechanisms, weight-gain unmasks PCOS in those women who are genetically predisposed. Conversely, even modest weight-loss of just 5 % body weight in obese women with PCOS often results in clinically meaningful improvements in reproductive, hyperandrogenic and metabolic dysfunction. Given inextricable interlinks between PCOS and obesity, novel therapies that promote weight-loss, including activation of brown adipose tissue, remain perhaps our most promising future therapeutic options for obese women with PCOS.

Keywords

PCOS Obesity Metabolic dysfunction Weight-loss 

Notes

Conflicting Interests and Financial Disclosure

The authors have nothing to declare.

References

  1. 1.
    Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992;36(1):105–11.CrossRefGoogle Scholar
  2. 2.
    Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80(9):2586–93.PubMedGoogle Scholar
  3. 3.
    Taponen S, Martikainen H, Jarvelin MR, Laitinen J, Pouta A, Hartikainen AL, et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab. 2003;88(1):141–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65(2):137–45.CrossRefGoogle Scholar
  5. 5.
    Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434–8.PubMedGoogle Scholar
  6. 6.
    Legro RS. The genetics of obesity. Lessons for polycystic ovary syndrome. Ann N Y Acad Sci. 2000;900:193–202.CrossRefPubMedGoogle Scholar
  7. 7.
    Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10(8):2107–11.PubMedGoogle Scholar
  8. 8.
    Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon. 2014;14(11):e23235.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Barber TM, McCarthy MI, Franks S, Wass JA. Metabolic syndrome in polycystic ovary syndrome. Endokrynol Pol. 2007;58(1):34–41.PubMedGoogle Scholar
  10. 10.
    Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000;52(5):595–600.CrossRefGoogle Scholar
  11. 11.
    Barber TM, Bennett AJ, Groves CJ, Sovio U, Ruokonen A, Martikainen H, et al. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia. 2008;51(7):1153–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Ehrmann DA. Metabolic dysfunction in pcos: relationship to obstructive sleep apnea. Steroids. 2012;77(4):290–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Nitsche K, Ehrmann DA. Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2010;24(5):717–30.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–94.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39(6):724–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Li T, Wu K, You L, Xing X, Wang P, Cui L, et al. Common variant rs9939609 in gene FTO confers risk to polycystic ovary syndrome. PLoS One. 2013;8(7):e66250.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Ewens KG, Jones MR, Ankener W, Stewart DR, Urbanek M, Dunaif A, et al. FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS One. 2011;6(1):e16390.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Yan Q, Hong J, Gu W, Zhang Y, Liu Q, Su Y, et al. Association of the common rs9939609 variant of FTO gene with polycystic ovary syndrome in Chinese women. Endocrine. 2009;36(3):377–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Walley AJ, Blakemore AI, Froguel P. Genetics of obesity and the prediction of risk for health. Hum Mol Genet. 2006;15(Spec No 2):R124–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13):853–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030.CrossRefPubMedGoogle Scholar
  23. 23.
    Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165–74.CrossRefPubMedGoogle Scholar
  24. 24.
    Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800.PubMedGoogle Scholar
  25. 25.
    Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res. 2001;56:295–308.CrossRefPubMedGoogle Scholar
  26. 26.
    Nestler JE, Strauss 3rd JF. Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am. 1991;20(4):807–23.PubMedGoogle Scholar
  27. 27.
    Franks S, White D, Willis D. Mechanisms of anovulation in polycystic ovary syndrome. In: Filicori M, Flamigni C, editors. The ovary: regulation, dysfunction and treatment. Amsterdam: Elsevier; 1996.Google Scholar
  28. 28.
    White D, Leigh A, Wilson C, Donaldson A, Franks S. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1995;42(5):475–81.CrossRefGoogle Scholar
  29. 29.
    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod. 2000;15(6):1266–74.CrossRefPubMedGoogle Scholar
  30. 30.
    Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A, et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf). 1993;39(3):351–5.CrossRefGoogle Scholar
  31. 31.
    Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab. 1998;83(11):3984–91.PubMedGoogle Scholar
  32. 32.
    Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86(4):1626–32.PubMedGoogle Scholar
  33. 33.
    Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem. 2005;51(6):931–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Adashi EY, Hsueh AJ, Yen SS. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology. 1981;108(4):1441–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72(1):83–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Yki-Jarvinen H, Makimattila S, Utriainen T, Rutanen EM. Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab. 1995;80(11):3227–32.PubMedGoogle Scholar
  37. 37.
    Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105(3):311–20.PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Rice S, Christoforidis N, Gadd C, Nikolaou D, Seyani L, Donaldson A, et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod. 2005;20(2):373–81.CrossRefPubMedGoogle Scholar
  39. 39.
    Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, et al. Increased 5{alpha}-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(9):3558–66.CrossRefPubMedGoogle Scholar
  40. 40.
    Barber TM, Franks S. Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol. 2013;373(1–2):68–76.CrossRefPubMedGoogle Scholar
  41. 41.
    Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009;15(3):297–307.CrossRefPubMedGoogle Scholar
  42. 42.
    Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol. 2008;284(1–2):38–45.CrossRefPubMedGoogle Scholar
  43. 43.
    Iniguez G, Torrealba IM, Avila A, Cassorla F, Codner E. Adiponectin serum levels and their relationships to androgen concentrations and ovarian volume during puberty in girls with type 1 diabetes mellitus. Horm Res. 2008;70(2):112–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279(13):12152–62.CrossRefPubMedGoogle Scholar
  45. 45.
    Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 2004;94(4):e27–31.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Barber TM, Hazell M, Christodoulides C, Golding SJ, Alvey C, Burling K, et al. Serum levels of retinol-binding protein 4 and adiponectin in women with polycystic ovary syndrome: associations with visceral fat but no evidence for fat mass-independent effects on pathogenesis in this condition. J Clin Endocrinol Metab. 2008;93(7):2859–65.CrossRefPubMedGoogle Scholar
  47. 47.
    Yildiz BO, Bozdag G, Otegen U, Harmanci A, Boynukalin K, Vural Z, et al. Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS. Reprod Biomed Online. 2010;20(1):150–5.CrossRefPubMedGoogle Scholar
  48. 48.
    Cekmez F, Cekmez Y, Pirgon O, Emre Canpolat F, Aydinoz S, Metin Ipcioglu O, et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. Eur Cytokine Netw. 2011;22(1):32–7.PubMedGoogle Scholar
  49. 49.
    Dikmen E, Tarkun I, Canturk Z, Cetinarslan B. Plasma visfatin level in women with polycystic ovary syndrome. Gynecol Endocrinol. 2011;27(7):475–9.CrossRefPubMedGoogle Scholar
  50. 50.
    Jongwutiwes T, Lertvikool S, Leelaphiwat S, Rattanasiri S, Jultanmas R, Weerakiet S. Serum visfatin in Asian women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25(8):536–42.CrossRefPubMedGoogle Scholar
  51. 51.
    Munir I, Yen HW, Baruth T, Tarkowski R, Azziz R, Magoffin DA, et al. Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(8):4852–7.CrossRefPubMedGoogle Scholar
  52. 52.
    The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.CrossRefGoogle Scholar
  53. 53.
    Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007;66(4):513–7.Google Scholar
  54. 54.
    Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligo-anovulation with Polycystic Ovaries (PCO) but not overt hyperandrogenism. J Clin Endocrinol Metab. 2006;91(10):3922–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113(10):1210–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Ciftci CF, Uckuyu A, Karadeli E, Turhan E, Toprak E, Ozcimen EE. Phenotypic subgroups of polycystic ovary syndrome have different intra-renal resistance symptoms. Ginekol Pol. 2012;83(12):910–5.PubMedGoogle Scholar
  57. 57.
    Vaggopoulos V, Trakakis E, Chrelias C, Panagopoulos P, Basios G, Makridima S, et al. Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance. J Endocrinol Invest. 2013;36(7):478–84.PubMedGoogle Scholar
  58. 58.
    Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. 2006;91(12):4842–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(4):E628–37.CrossRefPubMedGoogle Scholar
  60. 60.
    Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG. 2009;116(12):1633–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999;84(1):137–44.PubMedGoogle Scholar
  62. 62.
    Marks SJ, Moore NR, Clark ML, Strauss BJ, Hockaday TD. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res. 1996;4(1):1–7.CrossRefPubMedGoogle Scholar
  63. 63.
    Zhuang XF, Zhao MM, Weng CL, Sun NL. Adipocytokines: a bridge connecting obesity and insulin resistance. Med Hypotheses. 2009;73(6):981–5.CrossRefPubMedGoogle Scholar
  64. 64.
    Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18(7):266–72.CrossRefPubMedGoogle Scholar
  65. 65.
    Horejsi R, Moller R, Rackl S, Giuliani A, Freytag U, Crailsheim K, et al. Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women. Am J Phys Anthropol. 2004;124(3):275–81.CrossRefPubMedGoogle Scholar
  66. 66.
    Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2003;79(6):1358–64.CrossRefPubMedGoogle Scholar
  67. 67.
    Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod. 2001;16(6):1255–60.CrossRefPubMedGoogle Scholar
  68. 68.
    Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab. 2005;90(11):6014–21.CrossRefPubMedGoogle Scholar
  69. 69.
    Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S, et al. Global adiposity rather than abnormal regional fat distribution characterises women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(3):999–1004.CrossRefPubMedGoogle Scholar
  70. 70.
    Manneras-Holm L, Leonhardt H, Kullberg J, Jennische E, Oden A, Holm G, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011;96(2):E304–11.CrossRefPubMedGoogle Scholar
  71. 71.
    Dolfing JG, Stassen CM, van Haard PM, Wolffenbuttel BH, Schweitzer DH. Comparison of MRI-assessed body fat content between lean women with polycystic ovary syndrome (PCOS) and matched controls: less visceral fat with PCOS. Hum Reprod. 2011;26(6):1495–500.CrossRefPubMedGoogle Scholar
  72. 72.
    Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007;92(7):2500–5.CrossRefPubMedGoogle Scholar
  73. 73.
    Peragallo Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol. 2013;122(2 Pt 1):380–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Mirshahi M, Ayani E, Nicolas C, Golestaneh N, Ferrari P, Valamanesh F, et al. The blockade of mineralocorticoid hormone signaling provokes dramatic teratogenesis in cultured rat embryos. Int J Toxicol. 2002;21(3):191–9.CrossRefPubMedGoogle Scholar
  75. 75.
    Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.CrossRefPubMedGoogle Scholar
  76. 76.
    Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet. 2013;113(4):520–45.CrossRefPubMedGoogle Scholar
  77. 77.
    Bates GW, Legro RS. Longterm management of Polycystic Ovarian Syndrome (PCOS). Mol Cell Endocrinol. 2013;373(1–2):91–7.PubMedCentralCrossRefPubMedGoogle Scholar
  78. 78.
    Jakicic JM, Tate DF, Lang W, Davis KK, Polzien K, Neiberg RH, et al. Objective physical activity and weight loss in adults: the step-up randomized clinical trial. Obesity (Silver Spring). 2014;22(11):2284–92.CrossRefGoogle Scholar
  79. 79.
    Klimczak D, Szlendak-Sauer K, Radowicki S. Depression in relation to biochemical parameters and age in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2015;184:43–7.CrossRefPubMedGoogle Scholar
  80. 80.
    Bozdag G, Yildiz BO. Interventions for the metabolic dysfunction in polycystic ovary syndrome. Steroids. 2013;78(8):777–81.CrossRefPubMedGoogle Scholar
  81. 81.
    Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P, Katsikis I. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine. 2013;44(3):583–90.CrossRefPubMedGoogle Scholar
  82. 82.
    Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol (Lausanne). 2014;5:140.Google Scholar
  83. 83.
    Poher AL, Altirriba J, Veyrat-Durebex C, Rohner-Jeanrenaud F. Brown adipose tissue activity as a target for the treatment of obesity/insulin resistance. Front Physiol. 2015;6:4.PubMedCentralCrossRefPubMedGoogle Scholar
  84. 84.
    Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360(15):1509–17.PubMedCentralCrossRefPubMedGoogle Scholar
  85. 85.
    Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360(15):1518–25.CrossRefPubMedGoogle Scholar
  86. 86.
    Reddy NL, Jones TA, Wayte SC, Adesanya O, Sankar S, Yeo YC, et al. Identification of brown adipose tissue using MR imaging in a human adult with histological and immunohistochemical confirmation. J Clin Endocrinol Metab. 2014;99(1):E117–21.CrossRefPubMedGoogle Scholar
  87. 87.
    Barber TM, Franks S. Genetic basis of polycystic ovary syndrome. Expert Rev Endocrinol Metab. 2010;5(4):549–61.CrossRefGoogle Scholar
  88. 88.
    Sorensen AE, Wissing ML, Salo S, Englund AL, Dalgaard LT. MicroRNAs related to Polycystic Ovary Syndrome (PCOS). Genes (Basel). 2014;5(3):684–708.CrossRefGoogle Scholar
  89. 89.
    Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003;14(8):365–70.CrossRefPubMedGoogle Scholar
  90. 90.
    Sanchez N. A life course perspective on polycystic ovary syndrome. Int J Womens Health. 2014;6:115–22.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Thomas M. Barber
    • 1
    • 2
    Email author
  • George K. Dimitriadis
    • 1
    • 2
  • Stephen Franks
    • 3
  1. 1.Division of Translational and Systems MedicineWarwick Medical School, The University of Warwick, Clinical Sciences Research Laboratories, University Hospitals Coventry and WarwickshireCoventryUK
  2. 2.Warwickshire Institute for the Study of Diabetes, Endocrinology and MetabolismUniversity Hospitals Coventry and WarwickshireCoventryUK
  3. 3.Institute of Reproductive and Developmental BiologyImperial CollegeLondonUK

Personalised recommendations